| abstract |
Methods for making anti-PCSK9 antibody crystals, such antibody crystals and formulations comprising antibody crystals are described herein. In the crystals or formulations described herein, the anti-PCSK9 IgG may comprise an antibody, namely the 21B12 heavy and light chain complementarity determining regions (CDRs). Thus, in some embodiments, the antibody comprises a light chain complementarity region (CDR) of the CDRL1 sequence in SEQ ID NO: 9, a CDRL2 sequence in SEQ ID NO: 9, and a CDRL3 sequence in CDRL3 in SEQ ID NO: 9, and a SEQ ID NO: 5 is an IgG comprising the CDRH1 sequence heavy chain complementarity determining region (CDR) in CDR 5, CDRH2 sequence CDRH2 in SEQ ID NO: 5, and CDRH3 sequence CDRH3 in SEQ ID NO: 5. [Selection] Figure 1A |